Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine

BACKGROUND: We conducted a Phase I dose escalation trial of ADVAX, a DNA-based candidate HIV-1 vaccine expressing Clade C/B' env, gag, pol, nef, and tat genes. Sequences were derived from a prevalent circulating recombinant form in Yunnan, China, an area of high HIV-1 incidence. The objective w...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Vasan, Sandhya, Schlesinger, Sarah J., Huang, Yaoxing, Hurley, Arlene, Lombardo, Angela, Chen, Zhiwei, Than, Soe, Adesanya, Phumla, Bunce, Catherine, Boaz, Mark, Boyle, Rosanne, Sayeed, Eddy, Clark, Lorna, Dugin, Daniel, Schmidt, Claudia, Song, Yang, Seamons, Laura, Dally, Len, Ho, Martin, Smith, Carol, Markowitz, Martin, Cox, Josephine, Gill, Dilbinder K., Gilmour, Jill, Keefer, Michael C., Fast, Patricia, Ho, David D.
التنسيق: Artigo
اللغة:Inglês
منشور في: Public Library of Science 2010
الموضوعات:
Research Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC2799527/
https://ncbi.nlm.nih.gov/pubmed/20111582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0008617
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة